JP7657590B2 - がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤 - Google Patents

がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤 Download PDF

Info

Publication number
JP7657590B2
JP7657590B2 JP2020503374A JP2020503374A JP7657590B2 JP 7657590 B2 JP7657590 B2 JP 7657590B2 JP 2020503374 A JP2020503374 A JP 2020503374A JP 2020503374 A JP2020503374 A JP 2020503374A JP 7657590 B2 JP7657590 B2 JP 7657590B2
Authority
JP
Japan
Prior art keywords
cancer
agent
bad
naltrexol
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020503374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515649A (ja
JP2020515649A5 (enExample
Inventor
ダルグレイッシュ，アンガス
ルイ，ワイ
Original Assignee
エルディーエヌ ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1704910.7A external-priority patent/GB201704910D0/en
Priority claimed from GBGB1718806.1A external-priority patent/GB201718806D0/en
Application filed by エルディーエヌ ファーマ リミテッド filed Critical エルディーエヌ ファーマ リミテッド
Publication of JP2020515649A publication Critical patent/JP2020515649A/ja
Publication of JP2020515649A5 publication Critical patent/JP2020515649A5/ja
Priority to JP2024207994A priority Critical patent/JP2025027084A/ja
Application granted granted Critical
Publication of JP7657590B2 publication Critical patent/JP7657590B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020503374A 2017-03-28 2018-03-28 がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤 Active JP7657590B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024207994A JP2025027084A (ja) 2017-03-28 2024-11-29 がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1704910.7A GB201704910D0 (en) 2017-03-28 2017-03-28 High dose combi I
GB1704910.7 2017-03-28
GB1718806.1 2017-11-14
GBGB1718806.1A GB201718806D0 (en) 2017-11-14 2017-11-14 Breast cancer treatment
PCT/GB2018/050843 WO2018178690A1 (en) 2017-03-28 2018-03-28 An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024207994A Division JP2025027084A (ja) 2017-03-28 2024-11-29 がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤

Publications (3)

Publication Number Publication Date
JP2020515649A JP2020515649A (ja) 2020-05-28
JP2020515649A5 JP2020515649A5 (enExample) 2021-04-30
JP7657590B2 true JP7657590B2 (ja) 2025-04-07

Family

ID=61952738

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020503374A Active JP7657590B2 (ja) 2017-03-28 2018-03-28 がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤
JP2024207994A Pending JP2025027084A (ja) 2017-03-28 2024-11-29 がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024207994A Pending JP2025027084A (ja) 2017-03-28 2024-11-29 がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤

Country Status (9)

Country Link
US (1) US20200101066A1 (enExample)
EP (1) EP3600433B1 (enExample)
JP (2) JP7657590B2 (enExample)
KR (2) KR20200072445A (enExample)
CN (1) CN111050801B (enExample)
AU (1) AU2018244806B2 (enExample)
CA (1) CA3083850A1 (enExample)
ES (1) ES2897790T3 (enExample)
WO (1) WO2018178690A1 (enExample)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069262A1 (en) 2000-03-15 2003-04-10 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
US20030139352A1 (en) 2001-10-30 2003-07-24 Schoenhard Grant L. Inhibitors of ABC drug transporters in cancer cells
JP2008535850A (ja) 2005-04-07 2008-09-04 ハイシアム， インコーポレイテッド 物質乱用及び依存の治療方法
JP2015107918A (ja) 2012-02-14 2015-06-11 国立研究開発法人国立がん研究センター 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1479381A1 (en) * 2003-05-19 2004-11-24 Euro-Celtique S.A. Pharmaceutical dosage form comprising a solid solution
AU2006275914A1 (en) * 2005-07-27 2007-02-08 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
JP6008866B2 (ja) * 2010-12-03 2016-10-19 オレキシジェン・セラピューティクス・インコーポレーテッド ナルトレキソン療法における薬物バイオアベイラビリティの増加
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
WO2016061531A1 (en) * 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
GB201704911D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069262A1 (en) 2000-03-15 2003-04-10 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
US20030139352A1 (en) 2001-10-30 2003-07-24 Schoenhard Grant L. Inhibitors of ABC drug transporters in cancer cells
JP2008535850A (ja) 2005-04-07 2008-09-04 ハイシアム， インコーポレイテッド 物質乱用及び依存の治療方法
JP2015107918A (ja) 2012-02-14 2015-06-11 国立研究開発法人国立がん研究センター 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer，2015，Vol.121, Issue 16，pp.2681-2688
International Journal of Oncology，2016，vol.49，pp.793-802

Also Published As

Publication number Publication date
AU2018244806B2 (en) 2023-12-21
KR20240125082A (ko) 2024-08-19
ES2897790T3 (es) 2022-03-02
CN111050801A (zh) 2020-04-21
JP2020515649A (ja) 2020-05-28
CA3083850A1 (en) 2019-10-04
EP3600433A1 (en) 2020-02-05
AU2018244806A1 (en) 2019-11-21
KR20200072445A (ko) 2020-06-22
EP3600433B1 (en) 2021-05-05
WO2018178690A1 (en) 2018-10-04
CN111050801B (zh) 2023-03-28
JP2025027084A (ja) 2025-02-26
US20200101066A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
US10959984B2 (en) Methods for treating cancer with RORγ inhibitors
JP2023139230A (ja) 癌を治療するための併用療法
ES2954599T3 (es) Tratamiento de cáncer
US11351165B2 (en) Agent that increases the expression of the opioid kappa 1 for the treatment of cancer
JP7434185B2 (ja) 三置換ベンゾトリアゾール誘導体の使用方法
JP6620338B2 (ja) 低用量ナルトレキソンによるがん細胞の準備刺激
EP2968379B1 (en) Etoposide prodrugs for use in targeting cancer stem cells
JP2021505571A (ja) 末梢ｔ細胞リンパ腫および皮膚ｔ細胞リンパ腫を治療するための組成物および方法
AU2010224108A1 (en) Treatment of pancreatic cancer
US20100016421A1 (en) Methods for determining sensitivity to aminoflavones
JP7657590B2 (ja) がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤
JP7282072B2 (ja) 肺がんの治療に使用するための組み合わせ
JP7361779B2 (ja) がんに治療的処置をするためのｃ－１９ステロイドの組み合わせ
WO2021048417A1 (en) Combination therapies comprising dasatinib for the treatment of cholangiocarcinoma
US20230158042A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and hormone therapy agent
US20230149358A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and hormone therapy agent
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
Banerjee et al. Therapeutic paradigm underscoring glucosinolate sulforaphane in chemo-and radiosensitization of cancer: preclinical and clinical perspective
KR20250006934A (ko) 고형 종양을 치료하기 위한 이중 선택적 pi3k 델타 및 감마 억제제 및/또는 염-유도성 키나제 3 억제제
WO2021048418A1 (en) Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210319

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221220

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221220

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230207

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230227

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230228

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250326

R150 Certificate of patent or registration of utility model

Ref document number: 7657590

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150